MSD’s CAPVAXIVE vaccine has demonstrated promising results from the STRIDE-8 Phase III trial, which showed positive immune ...

Merck (NYSE:MRK) announced Thursday that its 21-valent pneumococcal vaccine, Capvaxive, approved in the U.S. to prevent ...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from STRIDE-8, a Phase 3 trial evaluating CAPVAXIVE™ (Pneumococcal ...

The rivalry between Pfizer and MSD in pneumococcal vaccines has dialled up a notch with the FDA approval of MSD’s new shot Capvaxive, the first to be aimed specifically at adults. The 21-valent ...

Merck’s STRIDE-8 phase 3 trial of Capvaxive demonstrates positive immune responses in adults with increased risk for pneumococcal disease: Rahway, New Jersey Thursday, October 1 ...

New Data to be Presented at IDWeek 2024 Reinforce Merck’s Broad and Diverse Vaccines and Infectious Disease Pipeline and ...

It received FDA approval and ACIP recommendation for its new pneumococcal conjugate vaccine, CAPVAXIVE, for adults. The ...

This type includes PCV15 (Vaxneuvance), PCV20 (Prevnar 20), and PCV21 (Capvaxive). The number in the name tells you how many types of bacteria the vaccine protects you against. Pneumococcal ...

RAHWAY, N.J. - Merck & Co., Inc. (NYSE: MRK) has announced positive results from the STRIDE-8 Phase 3 trial of its pneumococcal 21-valent conjugate vaccine, CAPVAXIVE, presented at IDWeek 2024. The ...

Merck (NYSE:MRK) announced Wednesday that its 21-valent pneumococcal vaccine, Capvaxive, approved in the U.S. to prevent pneumonia, generated positive immune responses in a Phase 3 trial for ...

MSD’s CAPVAXIVE vaccine has demonstrated promising results from the STRIDE-8 Phase III trial, which showed positive immune responses in adults at increased risk for pneumococcal disease.